FDA Launches Safety Review Of Asthma Drug Xolair
The U.S. Food and Drug Administration has announced that it is reviewing preliminary safety findings from an observational study that suggest asthma drug Xolair may be linked to an increased risk...To view the full article, register now.
Already a subscriber? Click here to view full article